News summary

Baili Tianheng announced that the first subject has been enrolled in the Phase III clinical trial of its innovative biopharmaceutical BL-M07D1 monotherapy for the treatment of HER2-positive breast cancercrashbandicootps1games, the indications range is wide, covering a variety of solid tumors.

Newsletter text

[Bailitianheng has made new progress in the field of biopharmaceuticals] On May 26, Bailitianheng announced that its independently developed innovative biopharmaceutical BL-M07D1 (HER2-ADC) has successfully found the first subject in a phase III clinical trial for locally advanced or metastatic HER2-positive breast cancer. BL-M07D1 is an ADC drug targeting HER2. Its treatment targets include breast cancer, gastric cancer, non-small cell lung cancer, gynecological and urinary tumors and other solid tumors.